FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891269224> ?p ?o ?g. }

• W2891269224 endingPage "16" @default.
• W2891269224 startingPage "7" @default.
• W2891269224 abstract "Introduction Programmed cell death-1 or ligand 1 (PD-(L)1) inhibitors are associated with immune-related adverse events. Conversely, little is known about the incidence of haematological toxicities across published trials. We have performed a systematic review and meta-analysis to evaluate the incidence of immunotherapy-related anaemia, neutropenia and thrombocytopenia among different tumour types, trials phases and anti-PD-(L)1 agents. Material and methods A PubMed, Embase and Cochrane library search on 23rd December 2017 and a review of references from relevant articles were done. Studies regarding haematological diseases were excluded. The pooled incidence rates weighted for the individual sample sizes were calculated according to fixed or random effect models. Incidence of all-grade and grade (G) III or higher anaemia were the primary end-points. Neutropenia, febrile neutropenia and thrombocytopenia were secondary end-points. Results Forty-seven studies of PD-(L)1 inhibitors for a total of 9324 evaluable patients were included in the meta-analysis. The overall incidence of anaemia during PD-(L)1 inhibitor was 9.8% (95% confidence interval [CI], 6–13.6%) for all-grade and 5% (95% CI, 3.3–6.7%) for G3-5 anaemia. The incidence was higher in diseases different from genitourinary, lung and melanoma, with avelumab and in phase II studies. In randomised trials, relative risk of all-grade anaemia for patients receiving anti-PD-(L)1 agents compared with control arms was 0.25 (95% CI, 0.16–0.39; p < 0.001). Incidence of all grades and G3-5 neutropenia and thrombocytopenia were 0.94%, 1.07%, 2.8% and 1.8%, respectively. Febrile neutropenia was 0.45%. Conclusions The incidence of PD-(L)1 inhibitor-related anaemia was not negligible. Severe neutropenia, thrombocytopenia and febrile neutropenia were rare. These findings are useful for clinicians and suggest that blood cell count should be checked before every cycle and support should be given when severe toxicity appears." @default.
• W2891269224 created "2018-09-27" @default.
• W2891269224 creator A5003293741 @default.
• W2891269224 creator A5032928173 @default.
• W2891269224 creator A5046233482 @default.
• W2891269224 creator A5058439511 @default.
• W2891269224 creator A5061179981 @default.
• W2891269224 creator A5065742446 @default.
• W2891269224 creator A5077706540 @default.
• W2891269224 date "2018-11-01" @default.
• W2891269224 modified "2023-10-16" @default.
• W2891269224 title "Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis" @default.
• W2891269224 cites W1940241680 @default.
• W2891269224 cites W1964435302 @default.
• W2891269224 cites W1971208896 @default.
• W2891269224 cites W1982488143 @default.
• W2891269224 cites W1990675339 @default.
• W2891269224 cites W2046972425 @default.
• W2891269224 cites W2086264703 @default.
• W2891269224 cites W2104347254 @default.
• W2891269224 cites W2106511606 @default.
• W2891269224 cites W2112121482 @default.
• W2891269224 cites W2118982164 @default.
• W2891269224 cites W2125112000 @default.
• W2891269224 cites W2126930838 @default.
• W2891269224 cites W2143488876 @default.
• W2891269224 cites W2147622445 @default.
• W2891269224 cites W2152897456 @default.
• W2891269224 cites W2153966492 @default.
• W2891269224 cites W2156353875 @default.
• W2891269224 cites W2160834915 @default.
• W2891269224 cites W2169351454 @default.
• W2891269224 cites W2177405394 @default.
• W2891269224 cites W2198093519 @default.
• W2891269224 cites W2222086386 @default.
• W2891269224 cites W2233818050 @default.
• W2891269224 cites W2265285917 @default.
• W2891269224 cites W2277326116 @default.
• W2891269224 cites W2281767740 @default.
• W2891269224 cites W2289841322 @default.
• W2891269224 cites W2293531514 @default.
• W2891269224 cites W2323655202 @default.
• W2891269224 cites W2339890238 @default.
• W2891269224 cites W2345415641 @default.
• W2891269224 cites W2510686645 @default.
• W2891269224 cites W2519279652 @default.
• W2891269224 cites W2527905628 @default.
• W2891269224 cites W2529484692 @default.
• W2891269224 cites W2530516001 @default.
• W2891269224 cites W2560704457 @default.
• W2891269224 cites W2588916311 @default.
• W2891269224 cites W2589072142 @default.
• W2891269224 cites W2592369722 @default.
• W2891269224 cites W2593193817 @default.
• W2891269224 cites W2594042408 @default.
• W2891269224 cites W2599354912 @default.
• W2891269224 cites W2602907503 @default.
• W2891269224 cites W2606367731 @default.
• W2891269224 cites W2635951006 @default.
• W2891269224 cites W2745624257 @default.
• W2891269224 cites W2745840031 @default.
• W2891269224 cites W2747272999 @default.
• W2891269224 cites W2753065806 @default.
• W2891269224 cites W2760661635 @default.
• W2891269224 cites W2762797139 @default.
• W2891269224 cites W2766016099 @default.
• W2891269224 cites W2766729634 @default.
• W2891269224 doi "https://doi.org/10.1016/j.ejca.2018.07.129" @default.
• W2891269224 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30196108" @default.
• W2891269224 hasPublicationYear "2018" @default.
• W2891269224 type Work @default.
• W2891269224 sameAs 2891269224 @default.
• W2891269224 citedByCount "51" @default.
• W2891269224 countsByYear W28912692242018 @default.
• W2891269224 countsByYear W28912692242019 @default.
• W2891269224 countsByYear W28912692242020 @default.
• W2891269224 countsByYear W28912692242021 @default.
• W2891269224 countsByYear W28912692242022 @default.
• W2891269224 countsByYear W28912692242023 @default.
• W2891269224 crossrefType "journal-article" @default.
• W2891269224 hasAuthorship W2891269224A5003293741 @default.
• W2891269224 hasAuthorship W2891269224A5032928173 @default.
• W2891269224 hasAuthorship W2891269224A5046233482 @default.
• W2891269224 hasAuthorship W2891269224A5058439511 @default.
• W2891269224 hasAuthorship W2891269224A5061179981 @default.
• W2891269224 hasAuthorship W2891269224A5065742446 @default.
• W2891269224 hasAuthorship W2891269224A5077706540 @default.
• W2891269224 hasConcept C120665830 @default.
• W2891269224 hasConcept C121332964 @default.
• W2891269224 hasConcept C126322002 @default.
• W2891269224 hasConcept C197934379 @default.
• W2891269224 hasConcept C2776694085 @default.
• W2891269224 hasConcept C2777063308 @default.
• W2891269224 hasConcept C44249647 @default.
• W2891269224 hasConcept C61511704 @default.
• W2891269224 hasConcept C71924100 @default.
• W2891269224 hasConcept C95190672 @default.
• W2891269224 hasConceptScore W2891269224C120665830 @default.

• next